What if treating a chronic condition didn’t always require medication and didn’t come with unwanted side effects?
Many disorders involve neurons that are difficult to target precisely, meaning traditional electrical stimulation activates entire neural bundles instead of just the fibres that matter. This lack of selectivity can reduce effectiveness and cause discomfort or unintended side-effects.
At imec at Holst Centre
We are developing high-precision neuromodulation technologies designed to address this challenge. Our research includes new stimulation methods such as intermittent interferential current stimulation (i²CS), along with miniaturised electronics, closed-loop solutions, and wireless powering approaches. These innovations aim to activate only specific neurons, delivering more precise neuromodulation with reduced activation of non-target regions.
What is sPNS?
Our focus
This selective approach can support the development of next generation bioelectronic therapies that are more effective, more comfortable, and easier to tailor to patient needs. By improving precision and reducing unwanted stimulation, these technologies offer a pathway toward safer, better-tolerated alternatives or complements to drug-based treatments for disorders ranging from depression to chronic pain, from epilepsy to anxiety.
— Work with us
Collaborate on impact
Join one of our shared R&D programs or start a dedicated collaboration — together we secure positions in the value chains that will define the future.